newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / / Benzinga

Oral Semaglutide Shows Superior Glycaemic Control.

The PIONEER TEENS trial is the first to evaluate an oral GLP-1 receptor agonist in youth.

KEY POINTS
COMPANIES
Read the full story on Benzinga →
Share X LinkedIn

Summarized by Newsio from Benzinga. How we summarize →